149 related articles for article (PubMed ID: 19682862)
1. Efficacy of moxifloxacin or gatifloxacin as prophylaxis against experimental murine Brucella melitensis infection.
Atkins HS; Spencer S; Brew SD; Laws TR; Thirlwall RE; MacMillan AP; Brooks TJ; Simpson AJ
Int J Antimicrob Agents; 2009 Nov; 34(5):471-3. PubMed ID: 19682862
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of ciprofloxacin versus doxycycline as prophylaxis against experimental murine Brucella melitensis infection.
Atkins HS; Spencer S; Brew SD; Jenner DC; Russell P; MacMillan AP; Eley SM; Simpson AJ
Int J Antimicrob Agents; 2009 Nov; 34(5):474-6. PubMed ID: 19500948
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis against experimental murine Brucella melitensis infection.
Atkins HS; Spencer S; Brew SD; Jenner DC; Sefton AM; MacMillan AP; Brooks TJ; Simpson AJ
Int J Antimicrob Agents; 2010 Jul; 36(1):66-8. PubMed ID: 20022474
[TBL] [Abstract][Full Text] [Related]
4. In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice.
Piercy T; Steward J; Lever MS; Brooks TJ
J Antimicrob Chemother; 2005 Dec; 56(6):1069-73. PubMed ID: 16223941
[TBL] [Abstract][Full Text] [Related]
5. Comparison of gatifloxacin, moxifloxacin and ciprofloxacin for treatment of experimental Burkholderia pseudomallei infection.
Steward J; Piercy T; Lever MS; Nelson M; Simpson AJ; Brooks TJ
J Antimicrob Chemother; 2005 Apr; 55(4):523-7. PubMed ID: 15731198
[TBL] [Abstract][Full Text] [Related]
6. Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin.
Steward J; Piercy T; Lever MS; Simpson AJ; Brooks TJ
Int J Antimicrob Agents; 2006 May; 27(5):439-43. PubMed ID: 16621457
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of several antibiotic combinations against Brucella melitensis Rev 1 experimental infection in BALB/c mice.
Grilló MJ; De Miguel MJ; Muñoz PM; Marín CM; Ariza J; Blasco JM
J Antimicrob Chemother; 2006 Sep; 58(3):622-6. PubMed ID: 16849379
[TBL] [Abstract][Full Text] [Related]
8. The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photorefractive keratectomy.
Burka JM; Bower KS; Vanroekel RC; Stutzman RD; Kuzmowych CP; Howard RS
Am J Ophthalmol; 2005 Jul; 140(1):83-7. PubMed ID: 15953577
[TBL] [Abstract][Full Text] [Related]
9. Effect of recombinant murine granulocyte colony-stimulating factor with or without fluoroquinolone therapy on mixed-infection abscesses in mice.
Stearne LE; Vonk AG; Kullberg BJ; Gyssens IC
Antimicrob Agents Chemother; 2005 Sep; 49(9):3668-75. PubMed ID: 16127038
[TBL] [Abstract][Full Text] [Related]
10. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
Scoper SV
Adv Ther; 2008 Oct; 25(10):979-94. PubMed ID: 18836691
[TBL] [Abstract][Full Text] [Related]
11. Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones.
Steward J; Lever MS; Simpson AJ; Sefton AM; Brooks TJ
J Antimicrob Chemother; 2004 Jul; 54(1):95-9. PubMed ID: 15163650
[TBL] [Abstract][Full Text] [Related]
12. Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin.
Deramo VA; Lai JC; Fastenberg DM; Udell IJ
Am J Ophthalmol; 2006 Nov; 142(5):721-5. PubMed ID: 16989762
[TBL] [Abstract][Full Text] [Related]
13. Successful moxifloxacin prophylaxis against experimental streptococcal aortic valve endocarditis.
Sakka V; Galani L; Pefanis A; Iliopoulos D; Athanasopoulos G; Donta I; Giamarellou H
J Antimicrob Chemother; 2005 Dec; 56(6):1160-2. PubMed ID: 16204339
[TBL] [Abstract][Full Text] [Related]
14. Comparison of rifampicin and moxifloxacin efficacy in an experimental model of animal brucellosis.
Sezak N; Kuruuzum Z; Cakir N; Yuce A
J Chemother; 2008 Feb; 20(1):58-62. PubMed ID: 18343745
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial efficacy of prophylactic gatifloxacin 0.3% and moxifloxacin 0.5% in patients undergoing phacoemulsification surgery.
Bucci FA; Amico LM; Evans RE
Eye Contact Lens; 2008 Jan; 34(1):39-42. PubMed ID: 18180682
[TBL] [Abstract][Full Text] [Related]
16. Inadequate azithromycin activity against Brucella melitensis in mice with acute or chronic infections.
Domingo S; Gamazo C
J Chemother; 1996 Feb; 8(1):55-8. PubMed ID: 8835110
[TBL] [Abstract][Full Text] [Related]
17. Fluoroquinolone therapy in a rabbit model of post-LASIK methicillin-resistant Staphylococcus aureus keratitis.
Balzli CL; McCormick CC; Caballero AR; Huang B; Wigington L; Smith E; Tang A; O'Callaghan RJ
J Cataract Refract Surg; 2008 Feb; 34(2):295-301. PubMed ID: 18242457
[TBL] [Abstract][Full Text] [Related]
18. Targeting Brucella melitensis with polymeric nanoparticles containing streptomycin and doxycycline.
Seleem MN; Jain N; Pothayee N; Ranjan A; Riffle JS; Sriranganathan N
FEMS Microbiol Lett; 2009 May; 294(1):24-31. PubMed ID: 19493005
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium.
Sano C; Tatano Y; Shimizu T; Yamabe S; Sato K; Tomioka H
Int J Antimicrob Agents; 2011 Apr; 37(4):296-301. PubMed ID: 21353489
[TBL] [Abstract][Full Text] [Related]
20. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
